A Phase 3 interventional study of Desloratadine and Placebo in Urticaria, sponsored by Organon and Co. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-06-18.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing desloratadine in Urticaria — none open to participants now, none under way, none of them phase 3. desloratadine · Urticaria.
Among the 10 studies testing desloratadine in Urticaria, this one is the 2nd largest by enrollment, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 9th registered.
148 studies on the registry are indexed under Urticaria; 19 are open to participants now.
Browse Urticaria studies →None of the 10 studies testing desloratadine in Urticaria is open now. The open studies under Urticaria, anywhere →
desloratadine: first FDA approval 2001 (CLARINEX), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 239 is above the median of 51 across 104 interventional studies indexed under Urticaria.
Median enrollment 139 across the 10 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Organon & Co. has 9 studies filed under Urticaria — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing desloratadine in Urticaria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with chronic urticaria. The primary hypothesis is that the efficacy of desloratadine 10 mg and 5 mg is superior to placebo as based on the change from Baseline in the sum score of pruritus/itch and rash as assessed by the Investigator at Week 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks
Drug: Desloratadine · Drug: Placebo
Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks
Drug: Desloratadine
Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks
Drug: Placebo
Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
Placebo tablets, given orally, once daily in the evening for 2 weeks
Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2
The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The score used for pruritus/itch was the higher of the day or night scores (0=Asymptomatic to 4=Severe). The Investigator also assessed the severity of participant rash using the overall rash score (0=No rash to 3=Looks very bad). The sum of the pruritus/itch score (0-4) and rash score (0-3) could range from 0 to 7, with a higher sum score indicating greater severity. The change from Baseline in the sum of the pruritus/itch and overall rash scores at the Week 2 clinic visit was calculated.
Time frame: Baseline Visit and Week 2 Visit
Number of Participants Who Experienced at Least One Adverse Event (AE)
An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE.
Time frame: Up to 4 weeks (Up to 2 weeks after last dose of study drug)
Number of Participants Who Discontinued Study Drug Due to an AE
An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE.
Time frame: Up to 2 weeks
Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Day 3 and Week 1
The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The score used for pruritus/itch was the higher of the day or night scores (0=Asymptomatic to 4=Severe). The Investigator also assessed the severity of participant rash using the overall rash score (0=No rash to 3=Looks very bad). The sum of the pruritus/itch score (0-4) and rash score (0-3) could range from 0 to 7, with a higher sum score indicating greater severity. The changes from Baseline in the sum of the pruritus/itch and overall rash scores at the Day 3 and Week 1 clinic visits were calculated.
Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit
Change From Baseline in the Pruritus/Itch Score Assessed by Investigator at Day 3, Week 1 and Week 2
The Investigator assessed the severity of participant pruritus/itch during the daytime and nighttime (0=Asymptomatic to 4=Severe). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher score indicating greater severity. The changes from Baseline in the sum of the daytime and nighttime scores at the Day 3, Week 1 and Week 2 clinic visits were calculated.
Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Change From Baseline in the Rash Score Assessed by Investigator at Day 3, Week 1 and Week 2
The Investigator assessed the severity of participant rash (erythema: 0=no symptom to 3=intensive redness, and wheal: 0=no symptom to 3=significant ridge). The sum score for erythema plus wheal could range from 0 to 6, with a higher score indicating greater severity. The changes from Baseline in the sum score for erythema plus wheal at the Day 3, Week 1 and Week 2 clinic visits were calculated.
Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Number of Participants With a Moderate or Remarkable Improvement in the Global Improvement Rate of Both Pruritus/Itch and Rash (Erythema and Wheal) Assessed by the Investigator at Day 3, Week 1 and Week 2
The global improvement judgment criteria were used to assess overall improvement in pruritus/itch and rash. The Investigator assessed participant global improvement according to 5 grades (Grade 1=Remarkable improvement to Grade 5=Aggravated). The number of participants with moderate or remarkable improvements was calculated. Remarkable improvement (Grade 1) was defined as both pruritus/itch and rash (erythema and wheal) disappeared, or pruritus/itch disappeared and rash (erythema and wheal) was apparently improved. Moderate improvement (Grade 2) was defined as both pruritus/itch and rash (erythema and wheal) were greatly improved.
Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Change From Baseline in the Pruritus/Itch Score Reported in Participant Diaries at Day 3, Week 1 and Week 2
Participants assessed the severity of their pruritus/itch during the daytime and nighttime (0=asymptomatic to 4=severe). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher score indicating greater severity. The changes from Baseline in the sum of the daytime and nighttime scores at the Day 3, Week 1 and Week 2 clinic visits were calculated.
Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Change From Baseline in Pruritus/Itch on a Visual Analog Scale (VAS) Reported by Participants at Day 3, Week 1 and Week 2
Participants assessed the degree of their pruritus/itching using a 100-mm visual analog scale (VAS) (0 mm=No itch to 100 mm=Worst imaginable itch), with a higher score indicating more severe itching. The changes from Baseline in participant-assessed pruritus/itch at the Day 3, Week 1 and Week 2 clinic visits were calculated.
Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Change From Baseline in the Rash Score Reported in Participant Diaries at Day 3, Week 1 and Week 2
Participants assessed the severity of their rash (erythema: 0=no symptom to 3=intensive redness, and wheal: 0=no symptom to 3=significant ridge). The sum score for erythema plus wheal could range from 0 to 6, with a higher score indicating greater severity. The changes from Baseline in the sum score for erythema plus wheal at the Day 3, Week 1 and Week 2 clinic visits were calculated.
Time frame: Baseline Visit and Day 3 Visit, Week 1 Visit, Week 2 Visit
Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score Reported by Participants at Week 1 and Week 2
The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses to questions about the effect of participant skin problems on life ranged from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life. Participants \>=16 years of age completed the DLQI questionnaire about the condition of their skin over the previous week. The changes from Baseline in the DLQI total score at the Week 1 and Week 2 clinic visits were calculated.
Time frame: Baseline Visit and Week 1 Visit, Week 2 Visit
| Milestone | Desloratadine 5 mg | Desloratadine 10 mg | Placebo |
|---|---|---|---|
| Started | 80 | 79 | 80 |
| Completed | 80 | 78 | 71 |
| Not completed | 0 | 1 | 9 |
| Withdrew: Adverse event | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 6 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The score used for pruritus/itch was the higher of the day or night scores (0=Asymptomatic to 4=Severe). The Investigator also assessed the severity of participant rash using the overall rash score (0=No rash to 3=Looks very bad). The sum of the pruritus/itch score (0-4) and rash score (0-3) could range from 0 to 7, with a higher sum score indicating greater severity. The change from Baseline in the sum of the pruritus/itch and overall rash scores at the Week 2 clinic visit was calculated.
| Score on a Scale | Desloratadine 5 mg | Desloratadine 10 mg | Placebo |
|---|---|---|---|
| Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2 | -3.19 (-3.56 to -2.83) | -3.16 (-3.52 to -2.79) | -2.02 (-2.40 to -1.65) |
An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE.
| Participants | Desloratadine 5 mg | Desloratadine 10 mg | Placebo | Desloratadine 5 mg→Placebo |
|---|---|---|---|---|
| Number of Participants Who Experienced at Least One Adverse Event (AE) | 24 | 18 | 16 | 0 |
An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE.
| Participants | Desloratadine 5 mg | Desloratadine 10 mg | Placebo | Desloratadine 5 mg→Placebo |
|---|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an AE | 0 | 0 | 2 | 0 |
The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The score used for pruritus/itch was the higher of the day or night scores (0=Asymptomatic to 4=Severe). The Investigator also assessed the severity of participant rash using the overall rash score (0=No rash to 3=Looks very bad). The sum of the pruritus/itch score (0-4) and rash score (0-3) could range from 0 to 7, with a higher sum score indicating greater severity. The changes from Baseline in the sum of the pruritus/itch and overall rash scores at the Day 3 and Week 1 clinic visits were calculated.
| Score on a Scale | Desloratadine 5 mg | Desloratadine 10 mg | Placebo |
|---|---|---|---|
| Change from Baseline at Day 3 | -2.57 (-2.91 to -2.23) | -2.75 (-3.09 to -2.41) | -0.80 (-1.14 to -0.46) |
| Change from Baseline at Week 1 | -3.01 (-3.34 to -2.68) | -3.16 (-3.50 to -2.83) | -1.39 (-1.72 to -1.06) |
The Investigator assessed the severity of participant pruritus/itch during the daytime and nighttime (0=Asymptomatic to 4=Severe). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher score indicating greater severity. The changes from Baseline in the sum of the daytime and nighttime scores at the Day 3, Week 1 and Week 2 clinic visits were calculated.
| Score on a Scale | Desloratadine 5 mg | Desloratadine 10 mg | Placebo |
|---|---|---|---|
| Change from Baseline at Day 3 | -2.62 (-2.97 to -2.27) | -2.72 (-3.07 to -2.37) | -0.61 (-0.95 to -0.26) |
| Change from Baseline at Week 1 | -2.98 (-3.35 to -2.61) | -3.13 (-3.50 to -2.76) | -1.38 (-1.75 to -1.01) |
| Change from Baseline at Week 2 | -3.17 (-3.56 to -2.77) | -3.21 (-3.60 to -2.81) | -1.91 (-2.31 to -1.50) |
The Investigator assessed the severity of participant rash (erythema: 0=no symptom to 3=intensive redness, and wheal: 0=no symptom to 3=significant ridge). The sum score for erythema plus wheal could range from 0 to 6, with a higher score indicating greater severity. The changes from Baseline in the sum score for erythema plus wheal at the Day 3, Week 1 and Week 2 clinic visits were calculated.
| Score on a Scale | Desloratadine 5 mg | Desloratadine 10 mg | Placebo |
|---|---|---|---|
| Change from Baseline at Day 3 | -2.31 (-2.63 to -2.00) | -2.61 (-2.93 to -2.29) | -0.99 (-1.31 to -0.67) |
| Change from Baseline at Week 1 | -2.65 (-2.97 to -2.33) | -2.98 (-3.30 to -2.66) | -1.44 (-1.76 to -1.12) |
| Change from Baseline at Week 2 | -2.94 (-3.28 to -2.61) | -2.91 (-3.25 to -2.57) | -1.98 (-2.33 to -1.64) |
The global improvement judgment criteria were used to assess overall improvement in pruritus/itch and rash. The Investigator assessed participant global improvement according to 5 grades (Grade 1=Remarkable improvement to Grade 5=Aggravated). The number of participants with moderate or remarkable improvements was calculated. Remarkable improvement (Grade 1) was defined as both pruritus/itch and rash (erythema and wheal) disappeared, or pruritus/itch disappeared and rash (erythema and wheal) was apparently improved. Moderate improvement (Grade 2) was defined as both pruritus/itch and rash (erythema and wheal) were greatly improved.
| Participants | Desloratadine 5 mg | Desloratadine 10 mg | Placebo |
|---|---|---|---|
| Day 3 | 54 | 55 | 15 |
| Week 1 | 54 | 58 | 32 |
| Week 2 | 59 | 53 | 38 |
Participants assessed the severity of their pruritus/itch during the daytime and nighttime (0=asymptomatic to 4=severe). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher score indicating greater severity. The changes from Baseline in the sum of the daytime and nighttime scores at the Day 3, Week 1 and Week 2 clinic visits were calculated.
| Score on a Scale | Desloratadine 5 mg | Desloratadine 10 mg | Placebo |
|---|---|---|---|
| Change from Baseline at Day 3 | -2.37 (-2.74 to -2.00) | -2.73 (-3.10 to -2.36) | -0.50 (-0.87 to -0.13) |
| Change from Baseline at Week 1 | -2.53 (-2.91 to -2.15) | -2.85 (-3.24 to -2.47) | -1.27 (-1.65 to -0.88) |
| Change from Baseline at Week 2 | -2.85 (-3.30 to -2.41) | -2.97 (-3.42 to -2.51) | -1.75 (-2.23 to -1.27) |
Participants assessed the degree of their pruritus/itching using a 100-mm visual analog scale (VAS) (0 mm=No itch to 100 mm=Worst imaginable itch), with a higher score indicating more severe itching. The changes from Baseline in participant-assessed pruritus/itch at the Day 3, Week 1 and Week 2 clinic visits were calculated.
| Score on a Scale | Desloratadine 5 mg | Desloratadine 10 mg | Placebo |
|---|---|---|---|
| Change from Baseline at Day 3 | -35.94 (-41.91 to -29.97) | -39.60 (-45.61 to -33.60) | -5.22 (-11.19 to 0.75) |
| Change from Baseline at Week 1 | -40.82 (-46.55 to -35.09) | -48.82 (-54.60 to -43.03) | -15.88 (-21.63 to -10.13) |
| Change from Baseline at Week 2 | -45.86 (-51.96 to -39.75) | -45.01 (-51.17 to -38.84) | -25.24 (-31.52 to -18.97) |
Participants assessed the severity of their rash (erythema: 0=no symptom to 3=intensive redness, and wheal: 0=no symptom to 3=significant ridge). The sum score for erythema plus wheal could range from 0 to 6, with a higher score indicating greater severity. The changes from Baseline in the sum score for erythema plus wheal at the Day 3, Week 1 and Week 2 clinic visits were calculated.
| Score on a Scale | Desloratadine 5 mg | Desloratadine 10 mg | Placebo |
|---|---|---|---|
| Change from Baseline at Day 3 | -2.21 (-2.57 to -1.85) | -2.31 (-2.67 to -1.94) | -0.77 (-1.13 to -0.40) |
| Change from Baseline at Week 1 | -2.15 (-2.50 to -1.81) | -2.43 (-2.77 to -2.08) | -1.17 (-1.52 to -0.83) |
| Change from Baseline at Week 2 | -2.51 (-2.88 to -2.13) | -2.45 (-2.83 to -2.06) | -1.70 (-2.11 to -1.29) |
The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses to questions about the effect of participant skin problems on life ranged from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life. Participants \>=16 years of age completed the DLQI questionnaire about the condition of their skin over the previous week. The changes from Baseline in the DLQI total score at the Week 1 and Week 2 clinic visits were calculated.
| Score on a Scale | Desloratadine 5 mg | Desloratadine 10 mg | Placebo |
|---|---|---|---|
| Change from Baseline at Week 1 | -3.82 (-4.52 to -3.12) | -4.08 (-4.78 to -3.37) | -1.60 (-2.31 to -0.89) |
| Change from Baseline at Week 2 | -4.10 (-4.83 to -3.38) | -4.01 (-4.74 to -3.28) | -2.53 (-3.28 to -1.78) |
Collected over Up to 4 weeks (Up to 2 weeks after last dose of study drug). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Desloratadine 5 mg | — | 0/80 (0%) | 10/80 (12.5%) |
| Desloratadine 10 mg | — | 0/79 (0%) | 8/79 (10.1%) |
| Placebo | — | 0/79 (0%) | 5/79 (6.3%) |
| Desloratadine 5 mg→Placebo | — | 0/1 (0%) | 0/1 (0%) |
| Event | Desloratadine 5 mg | Desloratadine 10 mg | Placebo | Desloratadine 5 mg→Placebo |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/80 | 3/79 | 2/79 | 0/1 |
| SomnolenceNervous system disorders | 3/80 | 5/79 | 3/79 | 0/1 |
| Age, Continuous(Years) | Desloratadine 5 mg | Desloratadine 10 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 38.4 ± 16.3 | 40.6 ± 15.8 | 39.3 ± 15.2 | 39.4 ± 15.7 |
| Sex: Female, Male(Participants) | Desloratadine 5 mg | Desloratadine 10 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 59 | 48 | 45 | 152 |
| Male | 21 | 31 | 35 | 87 |
No study locations are listed for this record.
Plan to share: No
Ran from Aug 2013 to primary completion in Feb 2014, 6 months.
Results were first posted in Oct 2014, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Desloratadine